Discriminating Between Response Types in Infliximab-Treated Patients With Crohn's Disease: Sensitivity and Specificity of Combined Assessment of Infliximab Trough Levels and Anti-Drug Antibodies

被引：0
|
作者：
Steenholdt, Casper
Thomsen, Ole O.
Brynskov, Jorn
Bendtzen, Klaus
Ainsworth, Mark A.
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
W1270
引用
收藏
页码：S687 / S688
页数：2
相关论文
共 50 条
  • [11] Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
    Steenholdt, Casper
    Bendtzen, Klaus
    Brynskov, Jorn
    Thomsen, Ole Ostergaard
    Ainsworth, Mark Andrew
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2011, 46 (03) : 310 - 318
  • [12] T cell response to infliximab in treated patients who develop anti-drug antibodies
    Vultaggio, A.
    Nencini, F.
    Pratesi, S.
    Zanieri, F.
    Maggi, E.
    Matucci, A.
    ALLERGY, 2016, 71 : 42 - 43
  • [13] The temporal evolution of anti-drug antibodies in IBD patients treated with infliximab
    Ben-Horin, Shomron
    Ungar, Bella
    Chowers, Yehuda
    Yavzori, Miri
    Picard, Orit
    Fudim, Ella
    Eliakim, Rami
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 145 - 145
  • [14] Is there a difference in trough levels and immunogenicity between Crohn's disease and ulcerative colitis patients treated with infliximab?
    Perdigoto, D.
    Macedo, C.
    Portela, F.
    Lopes, S.
    Ferreira, M.
    Ferreira, M.
    Mendes, S.
    Tome, L.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S475 - S475
  • [15] THE EARLY INFLIXIMAB LEVELS MONITORING CAN PREDICT THE DEVELOPEMENT OF ANTI-DRUG ANTIBODIES IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB
    Chamaida, P. -R.
    Pascual-Salcedo, D.
    Bonilla, M.
    Villalba, A.
    Lopez-Casla, M.
    Peiteado, D.
    Garcia-Carazo, S.
    Ramiro, S.
    Franco, K.
    Cajigas, D.
    Martin-Mola, E.
    Balsa, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 157 - 157
  • [16] Treatment persistency in infliximab-treated crohn's disease patients: A multicenter retrospective experience
    Keshavarazian, Ali
    Mayer, Lloyd
    Salzberg, Bruce
    Garone, Michael
    Finkelstein, Warren
    Cappa, Joseph
    Brand, Myron
    Hain, Jon
    Zelinger, David
    Hegedus, Ronald
    Diamond, Robert
    Campbell, Ulka
    Lane, Christi
    Stang, Paul
    Watson, John
    Cominelli, Fabio
    GASTROENTEROLOGY, 2007, 132 (04) : A145 - A145
  • [17] Cell sensitization to infliximab is detectable in a proportion of treated patients without anti-drug antibodies
    Nencini, F.
    Vultaggio, A.
    Pratesi, S.
    Maggi, E.
    Matucci, A.
    ALLERGY, 2015, 70 : 404 - 404
  • [18] Infliximab Drug Trough Levels Do Not Correlate With Infectious Complication Risk in Patients With Crohn's Disease
    Lee, Helen
    Schneider, Yecheskel
    Lichtenstein, Gary R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S358 - S358
  • [19] Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
    Pariente, Benjamin
    de Chambrun, Guillaume Pineton
    Krzysiek, Roman
    Desroches, Marine
    Louis, Gauthier
    De Cassan, Chiara
    Baudry, Clotilde
    Gornet, Jean-Marc
    Desreumaux, Pierre
    Emilie, Dominique
    Colombel, Jean-Frederic
    Allez, Matthieu
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (07) : 1199 - 1206
  • [20] Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis
    Siljehult, F.
    Arlestig, L.
    Eriksson, C.
    Rantapaa-Dahlqvist, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 (05) : 345 - 350
12345